Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And then on top of that, our software and services at Cue Care, Cue Lab, Cue Pharmacy, we'd expect those to also start gaining momentum |
| Now that we have fully built out the integrated care platform, we expect that adding new tests and treatment programs will be straightforward, and I'm really pleased with how the team continues to leverage the platform across new indications |
| And with regards to cannibalization, we've been having better-than-expected sales from our COVID-19 test |
| This is the best cash performance we've had since Q1 2022, which was the height of the Omicron |
| Looking ahead, we expect to have several molecular tests on the market in 2024, strengthening our expectations of a positive adjusted EBITDA by early 2025 |
| And then on spend, we're very proud of -- we're very happy with where our spend is right now and that allows us to -- the right amount of spend to play out our strategic priorities |
| In summary, I am pleased with the progress being made against our 2023 priorities of test menu expansion our integrated care platform and strong financial discipline |
| And you would have seen in the past when we've had higher volumes, we've posted over 60% margins |
| We continue to execute our key strategic priorities with strong financial discipline, having brought our cost down by $165 million on an annualized basis, exceeding our $150 million target |
| So with regards to what we're doing you can see that we've been executing with really strong fiscal discipline |
| What we think is that over the course of the respiratory season, there's a good chance that we'll be able to achieve the approvals for flu COVID, combo, flu de novo and RSV de novo |
| Our underlying cash burn rate improved from Q2 |
| The Cue Health Monitoring System has many new tests on the way, and we're very excited about the progress and our key priority of menu expansion |
| So as we sit here, we're really excited about the not-too-distant future when we have these approvals in hand |
| We are pleased with the sequential increase amidst the continued industry decline in COVID revenues |
| We remain optimistic that we will have additional authorization shortly and at these approvals along with new product launches will be the catalyst for revenue growth and reaching EBITDA breakeven in early 2025 |
| We believe we're getting close as we continue to have positive engagement with the FDA and have continued to add data where necessary as common in the review process |
| Cue reported total revenue of $17.5 million in the third quarter, exceeding expectations driven by stronger-than-anticipated COVID-19 test sales |
| So our cash performance this year of $17 million utilization, we're very happy with that performance |
| So I can't give you an exact timing, but we are optimistic that we can get them in the respiratory season |
| And when we think about our future products, there as we move away from COVID or the proportion away from COVID we do think we'd have a kind of price mix benefit as well on margins |
| We continue to be excited about this opportunity |
| As we said, we added a lot of really good data for especially our flu COVID and flu de novo applications and there's RSVs in process as well |
| We had non-COVID contribution revenue this quarter, and we continue to expect growth in the coming quarters as new products gain momentum |
| The team continues to drive solid progress in the development of this multiplex test |
| Additionally, we continue to execute on our near-term catalysts, including preparing for the launch of our flu + COVID multiplex, flu and RSV regulatory approvals and other new product offerings |
| So the Board and the management team, the key lens that we apply to every decision is increasing shareholder value |
| With this product, we believe we're adding a powerful tool for individuals at home, providers and enterprise seeking to make better informed health care decisions enable timely effective treatments |
| And not just this quarter, if you look at the whole year, in every quarter, our cash utilization has trended better quarter-on-quarter |
| Cue has a healthy balance sheet with $111.5 million of cash on hand as we continue to prioritize cash preservation |
| Statement |
|---|
| Q3 product gross profit was a loss of $7.4 million |
| Adjusted EBITDA was a loss of $36.6 million |
| It was obviously light in the second quarter |
| As a result, GAAP net loss in the third quarter was $47 million or $0.31 per diluted share |
| And the EBITDA loss was $35 million in the quarter, actually cash used was only $18 million |
| Q3 operating expenses were down 37% from Q4 2022 driven by cost reduction efforts |
| Gross profit is impacted by lower manufacturing volumes and also includes noncash items |
| Our operating expenses were down 37% from Q4 2022 and PPE capital expenditures in the quarter were $1.7 million, a 76% decrease from Q4 2022 |
| We made the decision, though, to delay the start of the clinical study to save cost as we prioritize promising near-term revenue-generating products, including the three tests and review with the FDA |
| Sales and marketing expenses were $7.1 million in the third quarter, a decrease of 63% from Q4 2022, driven by a decrease in digital and marketing costs |
| R&D expenses were $37.1 million for Q3, a decrease of 34% from $56.1 million of spend in Q4 2022 as we focus on development programs related to our respiratory and sexual health product offering |
| G&A expenses were $15.8 million during the quarter, a decline of 17% from Q4 2022 spend of $19.2 million |
| These risks and uncertainties include, but are not limited to, those outlined in today's call as well as other risks identified from time to time in our public statements and reports filed with the SEC |
| General herpes caused by HSV-1 or HSV-2 is the most common HCV in the United States with an infection in one out of every six sexually active people in the US |
| As you go down the P&L, I mean, gross profit is going to be impacted by volumes as well as mix |
| So it's not a -- it's pretty nuanced |
| On an adjusted basis, net loss was $63.6 million or $0.42 per diluted share |
Please consider a small donation if you think this website provides you with relevant information